Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
December 09, 2022 07:34 ET
|
Erasca, Inc.
Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500...
Erasca Announces Pricing of Underwritten Offering of Common Stock
December 09, 2022 07:32 ET
|
Erasca, Inc.
SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
November 30, 2022 08:00 ET
|
Erasca, Inc.
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed...
Erasca to Present at Upcoming Investor Conferences
November 22, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
November 09, 2022 16:01 ET
|
Erasca, Inc.
Positive preliminary monotherapy data for ERAS-007 and ERAS-601 support ongoing and future combination trials Signed CTCSAs with Eli Lilly to supply cetuximab in combination with ERAS-601 and with...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
October 20, 2022 08:00 ET
|
Erasca, Inc.
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with palbociclib in patients with KRAS- and NRAS-mutant colorectal cancer and KRAS-mutant pancreatic cancer ...
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
October 12, 2022 08:00 ET
|
Erasca, Inc.
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and tolerable profiles for combination development CNS-penetrant EGFR...
Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
September 26, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca to Present at the Morgan Stanley Global Healthcare Conference
September 09, 2022 08:31 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials
September 07, 2022 16:05 ET
|
Erasca, Inc.
23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601 ...